Drug intelligence / Profile preview

PTI-104

Development stage
Phase 1
Lead developer
Postsurgical Therapeutics
Modality
Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Intratumoral, Oral
01

Overview

**PTI-104** is a preclinical Postsurgical Therapeutics oncology program using the CLOTT approach for combinatorial local and oral targeted therapy in KRAS-mutated solid tumors. The program combines everolimus, an mTOR-pathway inhibitor, with trametinib, a MEK-pathway inhibitor, and uses PLGA-based controlled-release local delivery technology intended to provide sustained intratumoral exposure while limiting systemic toxicity. Postsurgical reports that non-GLP efficacy animal testing is in progress. ([pstherapeutics.com](https://pstherapeutics.com/pipeline-projects.html))

Other names
CLOTTCLOTT PlatformPTI104PTI-104PTI 104
02

Targets

FKBP1AMechanistic target of rapamycin complex 1Mechanistic target of rapamycin kinase complex 2MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)

Beyond the preview

Go deeper on PTI-104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTI-104.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call